Equillium Acquires Bioniz Therapeutics to Strengthen Immunology Portfolio
By Ayush Saxena & Lucy Haggerty
Pharma Deals Review: Vol 2022 Issue 2 (Table of Contents)
Published: 23 Feb-2022
DOI: 10.3833/pdr.v2022.i2.2673 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In a bid to expand its immunology franchise, Equillium has agreed to acquire Bioniz Therapeutics, a privately held clinical-stage biopharmaceutical company focused on developing novel structured domain peptides...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS